Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679884 | 0.90 | TACR3 (0.42) | BRAFTRPV1MCHR1SMOPTGES | |
| SCHEMBL6769957 | 0.89 | TRPV1 (0.41) | BRAFTRPV1SMOMTTP | |
| SCHEMBL6775048 | 0.89 | HPGDS (0.44) | HPGDSTRPV1MCHR1MTTP | |
| SCHEMBL6769816 | 0.85 | TRPV1 (0.46) | HPGDSTRPV1 | |
| SCHEMBL6765643 | 0.83 | TRPV1 (0.46) | BRAFTRPV1MCHR1PTGESMTTP | |
| SCHEMBL7688583 | 0.83 | HPGDS (0.45) | HPGDSTRPV1MTTP | |
| SCHEMBL6771609 | 0.82 | SMO (0.47) | TRPV1SMOMTTP | |
| SCHEMBL7926795 | 0.82 | MTTP (0.52) | MTTP | |
| SCHEMBL7920131 | 0.81 | MTTP (0.48) | TRPV1SMOMTTP | |
| SCHEMBL6052958 | 0.81 | MTTP (0.49) | HPGDSMTTP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713489-B2 | TREATMENT OF ATHEROSCLEROSIS, OBESITY, DIABETES, HYPERLIPIDEMIA, HYPERLIPOPROTEINEMIA, HYPERCHOLESTEROLEMIA, HYPERTRIGLYCERIDEMIA, HYPOALPHALIPOPROTEINEMIA, PANCREATITIS, MYOCARDIAL INFARCTION, STROKE, RESTENOSIS, OR SYNDROME X | PFIZER INC | 2004-03-30 | — | — | US | disclosed |
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | RUGGERI ROGER (US) | 2002-09-19 | — | — | US | disclosed |
| US-6369075-B1 | 7[4′-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and method of inhibiting the secretion of apolipoprotein B | PFIZER, INC. | 2002-04-09 | — | — | US | disclosed |
| EP-1099701-A1 | 7-[(4'-Trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132806-A1 | 7-[(4'-trifluoromethyl-biphenyl-2-carbonyl)amino]-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein B | APOB, CETP, PNLIP | HPGDS 989/4885BRAF 4186/4885TRPV1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.